What is Cellphire?
Cellphire Therapeutics operates at the intersection of advanced cellular biology and emergency medicine. The company is primarily focused on the development of innovative platelet-based therapies designed to mitigate the risks associated with controllable hemorrhage. Its core product pipeline, which includes freeze-dried platelet-derived hemostats and cryopreserved platelets, is currently undergoing rigorous Phase 2 clinical evaluation. By targeting the leading causes of preventable death in both military and civilian populations, Cellphire is establishing itself as a pivotal player in the life-sciences industry. The firm's commitment to enhancing hemostatic efficacy during critical care scenarios positions it as a high-value asset in the global medical technology landscape.
How much funding has Cellphire raised?
Cellphire has raised a total of $20.6M across 5 funding rounds:
Debt
$1M
Other Financing Round
$1.3M
Other Financing Round
$3M
Debt
$350K
Series A
$15M
Debt (2014): $1M, investors not publicly disclosed
Other Financing Round (2016): $1.3M led by Maryland Department of Commerce
Other Financing Round (2017): $3M supported by Maryland Department of Commerce
Debt (2020): $350K featuring PPP
Series A (2021): $15M backed by Simcah Management
Key Investors in Cellphire
Simcah Management
A private investment firm focused on providing strategic capital to high-growth companies in the healthcare and life sciences sectors.
Maryland Department of Commerce
A state-level agency dedicated to fostering economic growth and innovation by supporting technology-driven enterprises within the Maryland region.
PPP
Public-Private Partnership
What's next for Cellphire?
With the successful completion of its recent financing round, Cellphire is poised to transition its clinical assets toward late-stage trials and eventual regulatory submission. The strategic deployment of this capital will likely focus on scaling manufacturing capabilities and expanding the clinical footprint of its FPH and CPP product lines. As the company navigates the complexities of the FDA approval process, the focus will remain on demonstrating superior clinical outcomes in trauma-related bleeding. Future growth will be contingent upon the successful validation of its cellular therapy platform, which holds the potential to redefine standard-of-care protocols in emergency medicine and surgical intervention.
See full Cellphire company page
